Insider Transactions in Q4 2023 at Cyclo Therapeutics, Inc. (CYTH)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Shawn Cross Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,606
+50.0%
|
-
|
|
Nov 28
2023
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,512
+5.27%
|
-
|
|
Nov 28
2023
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,862
+8.34%
|
-
|
|
Nov 28
2023
|
William S Shanahan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,982
+8.36%
|
-
|
|
Nov 28
2023
|
Vivien Wong Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,488
+50.0%
|
-
|
|
Nov 28
2023
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,262
+3.02%
|
-
|
|
Nov 28
2023
|
William Conkling Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,466
+42.96%
|
-
|
|
Nov 28
2023
|
Ce Rick Strattan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,209
+2.85%
|
-
|
|
Oct 27
2023
|
Ce Rick Strattan Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,599
+13.57%
|
-
|
|
Oct 20
2023
|
N Scott Fine Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
299,402
+28.7%
|
$0
$0.71 P/Share
|
|
Oct 20
2023
|
Jeffrey Tate Chief Operating Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
29,941
+24.55%
|
$0
$0.71 P/Share
|
|
Oct 20
2023
|
Markus Sieger Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
59,881
+17.61%
|
$0
$0.71 P/Share
|
|
Oct 20
2023
|
Francis Patrick Ostronic Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
59,881
+16.24%
|
$0
$0.71 P/Share
|
|
Oct 20
2023
|
Rafael Holdings, Inc. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
2,514,970
+21.78%
|
$0
$0.71 P/Share
|